TREE NEWS reports: Moderna reported third-quarter revenue of $1.31 billion, up 29% year over year and above the $888.1 million market estimate. Earnings per share came in at 38 cents versus an expected loss of $1.09, while operating income was $130 million against a projected loss of $471.9 million. R&D spending was $583 million, below the $750 million estimate, and full-year capital expenditure is now expected at $200 million, narrowed from a prior $200 million-$300 million range.
Moderna Q3 revenue $1.31B, up 29% YoY, beating $888.1M estimate
AI take
The swing to operating profit alongside a sharp R&D undershoot is the real story here: cost discipline, not just demand, drove the beat, and the narrowed capex range reinforces that. That matters for a company whose spending trajectory has been the central debate. What's less clear is whether the lower R&D reflects efficiency or deferral, and whether the revenue beat is durable or timing-related. Whether spending stays contained while the pipeline advances is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
23m ago
White House adviser Hassett: Trump excited about Intel deal
30m ago
Six Chinese Brokers Complete Third Batch of Swap Facility Operations, Deploy First Stock Investments
39m ago
SK Hynix Sets Up US AI Investment Unit Hyaico With Up to $10B
40m ago
TSMC Weighs Producing Advanced Memory Chips
1h ago
Guotai Junan International Privatization Vote Set for End of Month, Delisting in February
1h ago
Chinese Rocket Engine Maker JiuZhouYunJian Files for IPO Coaching